Brain Tumor Therapeutics Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The brain tumor therapeutics market covers drug and treatment revenues for primary malignant and benign brain tumors as well as metastatic disease, with glioma representing the largest commercial sub-segment. Public incidence data from agencies such as the U.S. National Cancer Institute point to roughly 24,800 new malignant brain tumor cases expected in the United States in 2025, supporting a large and growing addressable population. Commercial valuations from multiple research providers cluster between $2.5 billion and $3.5 billion for 2024-2025, underscoring a market of meaningful but moderate scale relative to broader oncology therapeutics.

• •Global market valued at approximately $2.94 billion in 2025
• •Forecast period growth estimated at around 7.3% CAGR
• •Glioma is the leading indication by revenue contribution

Rising global incidence of primary brain tumors and CNS metastases, combined with growing approval and adoption of targeted and immunotherapies, is expanding the treatment landscape. Improvements in molecular diagnostics and biomarker-driven patient stratification are enabling more patients to receive tailored therapies, supporting revenue per treated case. Increased healthcare expenditure in emerging markets, alongside expanded reimbursement for novel oncology agents, is also widening access to advanced brain tumor treatments.

• •Rising brain tumor incidence and growing use of molecularly guided therapy
• •FDA and EMA approvals of targeted therapies and immunotherapies expanding treatment options
• •Expanding healthcare access and oncology spending in Asia-Pacific and Latin America

The market is commonly segmented by therapy type into chemotherapy, targeted therapy, immunotherapy, and others (including radiotherapy and surgery adjuncts), with chemotherapy historically dominant but targeted and immunotherapy gaining share. By indication, glioma accounts for the largest revenue pool, followed by meningioma, pituitary tumors, and other CNS malignancies. Geographically, North America holds the leading share due to high per-capita oncology spending and concentration of clinical trials, while Asia-Pacific is the fastest-growing region.

• •Therapy segmentation: chemotherapy, targeted therapy, immunotherapy, and others
• •Indication segmentation led by glioma, with meningioma and pituitary tumors as secondary segments
• •North America leads revenue share; Asia-Pacific is the fastest-growing region

What are the recent trends and outlook?

Key trends shaping the outlook include the rise of CAR-T and other cell therapies in solid tumor research, expansion of blood-brain barrier disrupting delivery technologies, and increasing use of AI-assisted imaging and diagnostics to guide treatment selection. Regulatory pathways for rare and pediatric brain tumor indications are being actively used to accelerate approvals, supporting a deeper pipeline. Looking ahead, the market is expected to continue mid- to high-single-digit growth as targeted and immunotherapeutic agents gain share and as precision oncology becomes standard of care.

• •Growing pipeline activity in CAR-T, antibody-drug conjugates, and blood-brain barrier technologies
• •Increasing use of FDA orphan and rare pediatric disease pathways to accelerate approvals
• •AI-enabled diagnostics and biomarker-driven treatment selection expected to support premium pricing and adoption